A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ReAlec
- Sponsors Roche
- 07 Nov 2023 Planned End Date changed from 9 Apr 2027 to 10 May 2027.
- 07 Nov 2023 Planned primary completion date changed from 9 Apr 2027 to 10 May 2027.
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.